Publications by authors named "M Vanmechelen"
Article Synopsis
- - Enteric glia are important players in the tumor microenvironment of colorectal cancer and may influence cancer development.
- - These glial cells change their characteristics to help immune cells like monocytes become more supportive of tumor growth, indicating a complex interaction within the tumor.
- - A higher presence of enteric glia correlates with poorer outcomes in colorectal cancer cases, suggesting their role in disease progression.
Glioblastoma (GBM) continues to exhibit a discouraging survival rate despite extensive research into new treatments. One factor contributing to its poor prognosis is the tumor's immunosuppressive microenvironment, in which the kynurenine pathway (KP) plays a significant role. This study aimed to explore how KP impacts the survival of newly diagnosed GBM patients.
View Article and Find Full Text PDFArticle Synopsis
- - The study focuses on glioblastoma (GBM), a dangerous brain cancer, and how patient-derived cancer organoids (PGOs) can help understand how tumors respond to treatments and why they sometimes don't work.
- - Researchers created PGOs from GBM samples and tested how they respond to a cancer drug called temozolomide (TMZ), finding that different organoids had different reactions based on their unique genetic traits.
- - The results show that PGOs can keep the important genetic differences of the tumors and could be used in the future to tailor treatments to individual patients and discover new drug targets.
Glioblastoma (GBM) remains the most malignant primary brain tumor, with a median survival rarely exceeding 2 years. Tumor heterogeneity and an immunosuppressive microenvironment are key factors contributing to the poor response rates of current therapeutic approaches. GBM-associated macrophages (GAMs) often exhibit immunosuppressive features that promote tumor progression.
View Article and Find Full Text PDFGlioblastoma Multiforme (GBM) remains the most common malignant primary brain tumor with a dismal prognosis that rarely exceeds beyond 2 years despite extensive therapy, which consists of maximal safe surgical resection, radiotherapy, and/or chemotherapy. Recently, it has become clear that GBM is not one homogeneous entity and that both intra-and intertumoral heterogeneity contributes significantly to differences in tumoral behavior which may consequently be responsible for differences in survival. Strikingly and in spite of its dismal prognosis, small fractions of GBM patients seem to display extremely long survival, defined as surviving over 10 years after diagnosis, compared to the large majority of patients.
View Article and Find Full Text PDF